Companies: 10,795·Total market cap: $144.5T
Dermata Therapeutics, Inc.

Dermata Therapeutics, Inc.

DRMANASDAQHealthcare● Active
$1.21
+$0.03(+2.54%)
Market Cap$824684
P/E Ratio
52W High$8
52W Low$1.1
Overview

Dermata Therapeutics, Inc. (DRMA) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · DRMA · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-5.31drma eps ttm · drma earnings per shareEarnings history
PE Ratio (TTM)drma pe ratio ttm · drma price to earningsPE Ratio deep dive
Revenue (TTM)0.00drma revenue ttm · drma annual revenueFull revenue history
Dividend YieldNo Dividenddoes drma pay dividends · drma dividend yieldDividend history
Shares Outstanding926,192drma shares outstanding · drma floatShares outstanding history
Next EarningsAug 18, 2026Est.drma earnings date · drma next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$0.00
202320242025
dermata therapeutics, inc. revenue · drma revenue 2025
FY 2025Net Income-$7.6M▲ +38.49% YoY
202320242025
dermata therapeutics, inc. net income · drma profit 2025
FY 2025EPS$-8.16▲ +89.84% YoY
202320242025
drma eps · dermata therapeutics, inc. earnings per share 2025
TTM:Revenue: $0.00Net Income: -$7.1MEPS: $-5.31View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy1 analystsis drma a buy · drma analyst rating
Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0
12-Month Price Target
$6.00Low
$1.21Current
$6.00Avg Target395.87% upside
$6.00High
drma price target · drma 12 month forecast

Total: 1 · Buy rate: 100.0%

The DRMA analyst consensus is Buy, based on ratings from 1 Wall Street analysts over the past 3 months. The average 12-month price target is $6.00, representing +395.87% upside from the current price of $1.21.

Stock Performance

Full History
1D+2.97%
1W-7.95%
1M-3.57%
3M-2.80%
YTD-47.63%
1Y-83.97%
5Y-99.99%

About Dermata Therapeutics, Inc.

CEOGerald T. Proehl
IPO DateAug 13, 2021
Employees8
CountryUS

Dermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed t…

what is dermata therapeutics, inc. · drma stock overview · dermata therapeutics, inc. company profile · who is dermata therapeutics, inc. ceo · drma NASDAQ · dermata therapeutics, inc. headquarters · dermata therapeutics, inc. business segments

About Stock Overview & Key Data

Dermata Therapeutics, Inc. (DRMA) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Aug 13, 2021. As of the latest trading session, DRMA stock price is $1.21, with a market capitalization of $824,684. The stock has returned -83.97% over the past 12 months and -47.63% year-to-date.

According to 1 Wall Street analysts, the consensus rating for Dermata Therapeutics, Inc. stock is Buy, with an average 12-month price target of $6.00. In fiscal year 2025, Dermata Therapeutics, Inc. reported revenue of — and net income of -$7.6M. For detailed data — including Dermata Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Dermata Therapeutics, Inc. (DRMA) stock price is $1.21. The stock is traded on NASDAQ under the ticker symbol DRMA. The 52-week range is $1.10 – $8.00.

DRMA stock priceDRMA quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice